[Thromboembolism--risk, prevention and therapy. Practice Guideline].
D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications; D002908:Chronic Disease; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D006814:Hungary; D007388:Internal Medicine / Q000379:methods*; D008403:Mass Screening; D009369:Neoplasms / Q000150:complications; D009422:Nervous System Diseases / Q000150:complications; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011322:Primary Prevention / Q000379:methods*; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods; D013514:Surgical Procedures, Operative / Q000009:adverse effects*; D013923:Thromboembolism / Q000209:etiology / Q000628:therapy; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control / Q000628:therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014812:Vitamin K